Bidirectional Association Between Depression and Fibromyalgia Syndrome: A Nationwide Longitudinal Study

Ma, Chang; Hsu, Ju Wei; Huang, Kou‐Yuan; Su, Tung Ping; Bai, Ya Mei; Li, Cheng Ta; Yang, Albert C.; Chang, Wen Han; Chen, Tzeng Ji; Tsai, Shih Jen; Chen, Mu Hong

doi:10.1016/j.jpain.2015.06.004

Cited by 115 publications

(76 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our results are in line with Cochrane Pain and Palliative and Supportive Care reviews that analyse drugs for fibromyalgia separately. Cording 2015 included six studies with 4238 participants in total in a review of milnacipran in fibromyalgia. The review authors concluded that milnacipran 100 mg or 200 mg per day was effective only for a minority of people in the treatment of pain due to fibromyalgia, providing moderate levels of pain relief (at least 30%) to about 40% of participants, compared with about 30% with placebo.…”

Section: Discussionmentioning

confidence: 99%

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia

Welsch

Üçeyler

Klose

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

Background Fibromyalgia is a clinically defined chronic condition of unknown etiology characterized by chronic widespread pain that often co‐exists with sleep disturbances, cognitive dysfunction and fatigue. People with fibromyalgia often report high disability levels and poor quality of life. Drug therapy, for example, with serotonin and noradrenaline reuptake inhibitors (SNRIs), focuses on reducing key symptoms and improving quality of life. This review updates and extends the 2013 version of this systematic review. Objectives To assess the efficacy, tolerability and safety of serotonin and noradrenaline reuptake inhibitors (SNRIs) compared with placebo or other active drug(s) in the treatment of fibromyalgia in adults. Search methods For this update we searched CENTRAL, MEDLINE, Embase, the US National Institutes of Health and the World Health Organization (WHO) International Clinical Trials Registry Platform for published and ongoing trials and examined the reference lists of reviewed articles, to 8 August 2017. Selection criteria We selected randomized, controlled trials of any formulation of SNRIs against placebo or any other active treatment of fibromyalgia in adults. Data collection and analysis Three review authors independently extracted data, examined study quality, and assessed risk of bias. For efficacy, we calculated the number needed to treat for an additional beneficial outcome (NNTB) for pain relief of 50% or greater and of 30% or greater, patient's global impression to be much or very much improved, dropout rates due to lack of efficacy, and the standardized mean differences (SMD) for fatigue, sleep problems, health‐related quality of life, mean pain intensity, depression, anxiety, disability, sexual function, cognitive disturbances and tenderness. For tolerability we calculated number needed to treat for an additional harmful outcome (NNTH) for withdrawals due to adverse events and for nausea, insomnia and somnolence as specific adverse events. For safety we calculated NNTH for serious adverse events. We undertook meta‐analysis using a random‐effects model. We assessed the evidence using GRADE and created a 'Summary of findings' table. Main results We added eight new studies with 1979 participants for a total of 18 included studies with 7903 participants. Seven studies investigated duloxetine and nine studies investigated milnacipran against placebo. One study compared desvenlafaxine with placebo and pregabalin. One study compared duloxetine with L‐carnitine. The majority of studies were at unclear or high risk of bias in three to five domains. The quality of evidence of all comparisons of desvenlafaxine, duloxetine and milnacipran versus placebo in studies with a parallel design was low due to concerns about publication bias and indirectness, and very low for serious adverse events due to concerns about...

show abstract

Section: Discussionmentioning

confidence: 99%

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia

Welsch

Üçeyler

Klose

et al. 2018

Cochrane Database of Systematic Reviews

View full text Add to dashboard Cite

show abstract

“…It is known that people with depression have a significantly higher risk of developing FM than the normal population, and depression develops in a significant proportion of FM patients (41). It has also been shown that there is a significant correlation between depressive symptoms and pain severity in FM patients, as in other chronic pain groups (42,43).…”

Section: Discussionmentioning

confidence: 99%

The relationship of childhood trauma, dissociative experiences and depression with pain in female patients with fibromyalgia: a cross-sectional study

Karaş¹,

Yıldırım²,

Küçükgöncü³

et al. 2017

Dusunen Adam

View full text Add to dashboard Cite

The relationship of childhood trauma, dissociative experiences and depression with pain in female patients with fibromyalgia: a cross-sectional studyObjective: The aim of this study was to investigate childhood trauma (CT) and dissociative symptoms in patients with fibromyalgia and evaluate the relationship of these characteristics with pain intensity. Methods: Forty patients followed up with fibromyalgia diagnosis in the physical therapy and rehabilitation outpatient clinic; and as a control group, 38 healthy individuals who have similar age, gender, and educational status, were included in the study. A sociodemographic and clinical data form, Beck Depression Inventory (BDI), Childhood Trauma Questionnaire (CTQ), Dissociative Experiences Scale (DES), Somatoform Dissociation Questionnaire (SDQ) and Visual Analogue Scale (VAS) were administered to participants. Results: Emotional abuse, physical neglect, physical abuse, CTQ total, SDQ and DES scores were found to be significantly higher in the fibromyalgia group than the control group. Only the difference for SDQ scores remained significant when a comparison made between groups by controlling depression levels. Somatoform dissociation scores were found to be a significant predictor of pain intensity in patients with fibromyalgia. Conclusion: Somatoform dissociative symptoms are found to be higher in patients with fibromyalgia than the control group. These symptoms may contribute to development and exacerbation of pain in fibromyalgia. Taking the dissociative symptoms into account have an important role in the treatment of patients with fibromyalgia who have a frequent history of CT, so the treatment of these patients should be carried out in cooperation with psychiatrists. Keywords: Childhood trauma, dissociation, fibromyalgia, somatoform dissociation ÖZET Kadın fibromiyalji hastalarında çocukluk çağı travmaları, disosiyatif yaşantılar ve depresyonun ağrı ile ilişkisi: Kesitsel bir çalışma Amaç: Bu çalışmanın amacı fibromiyalji (FM) hastalarında çocukluk çağı travmaları ile disosiyatif belirtileri araştırmak ve bu özelliklerin FM'deki ağrı şiddeti ile ilişkisini incelemektir. Yöntem: Fizik tedavi ve rehabilitasyon polikliniğinde fibromyalji tanısıyla takip edilmekte olan 40 hasta ile kontrol grubu olarak yaş, cinsiyet ve öğrenim durumu açısından benzer olan 38 sağlıklı kişi çalışmaya dahil edildi. Katılımcılara sosyodemografik ve klinik veri toplama formu, Beck Depresyon Ölçeği (BDÖ), Çocukluk Çağı Travmaları Ölçeği (ÇÇTÖ), Disosiyatif Yaşantılar Ölçeği (DYÖ), Somatoform Disosiyasyon Ölçeği (SDÖ) ve Görsel Analog Skala (GAS) uygulandı. Bulgular: FM grubunda duygusal istismar, fiziksel ihmal, fiziksel istismar, ÇÇTÖ toplam, SDÖ ve DYÖ puan ortalamaları kontrol grubuna göre anlamlı derecede yüksek bulundu. Gruplar arasında depresyon düzeyleri kontrol edilerek karşılaştırma yapıldığında ise sadece SDÖ puan farklılığının anlamlı olarak devam ettiği görüldü. Somatoform disosiyasyon puanlarının FM hastalarında ağrı şiddetinin anlamlı belirleyicisi olduğu saptan...

show abstract

“…This is not surprising since previous studies report the detrimental effects of comorbid depression and anxiety on overall symptom severity [42,43] and because of the bidirectional effect of depression in samples of patients with fibromyalgia [44]. Research has also demonstrated that patients with fibromyalgia with comorbid mood disorders and anxiety tend to have poorer outcomes than patients with predominantly physical and lower psychological symptoms [42].…”

Section: Discussionmentioning

confidence: 94%